Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Epigenetics Chromatin. 2019 Aug 9;12(1):50. doi: 10.1186/s13072-019-0297-2.
The MAPK/ERK signaling pathway is an essential regulator of numerous cell processes that are crucial for normal development as well as cancer progression. While much is known regarding MAPK/ERK signal conveyance from the cell membrane to the nucleus, the transcriptional and epigenetic mechanisms that govern gene expression downstream of MAPK signaling are not fully elucidated.
This study employed an integrated epigenome analysis approach to interrogate the effects of MAPK/ERK pathway inhibition on the global transcriptome, the active chromatin landscape, and protein-DNA interactions in 501mel melanoma cells. Treatment of these cells with the small-molecule MEK inhibitor AZD6244 induces hyperpigmentation, widespread gene expression changes including alteration of genes linked to pigmentation, and extensive epigenomic reprogramming of transcriptionally distinct regulatory regions associated with the active chromatin mark H3K27ac. Regulatory regions with differentially acetylated H3K27ac regions following AZD6244 treatment are enriched in transcription factor binding motifs of ETV/ETS and ATF family members as well as the lineage-determining factors MITF and SOX10. H3K27ac-dense enhancer clusters known as super-enhancers show similar transcription factor motif enrichment, and furthermore, these super-enhancers are associated with genes encoding MITF, SOX10, and ETV/ETS proteins. Along with genome-wide resetting of the active enhancer landscape, MEK inhibition also results in widespread SOX10 recruitment throughout the genome, including increased SOX10 binding density at H3K27ac-marked enhancers. Importantly, these MEK inhibitor-responsive enhancers marked by H3K27ac and occupied by SOX10 are located near melanocyte lineage-specific and pigmentation genes and overlap numerous human SNPs associated with pigmentation and melanoma phenotypes, highlighting the variants located within these regions for prioritization in future studies.
These results reveal the epigenetic reprogramming underlying the re-activation of melanocyte pigmentation and developmental transcriptional programs in 501mel cells in response to MEK inhibition and suggest extensive involvement of a MEK-SOX10 axis in the regulation of these processes. The dynamic chromatin changes identified here provide a rich genomic resource for further analyses of the molecular mechanisms governing the MAPK pathway in pigmentation- and melanocyte-associated diseases.
MAPK/ERK 信号通路是调节多种细胞过程的关键因子,这些过程对正常发育和癌症进展至关重要。尽管人们已经了解了 MAPK/ERK 信号从细胞膜向细胞核传递的情况,但调控 MAPK 信号下游基因表达的转录和表观遗传机制尚未完全阐明。
本研究采用整合的表观基因组分析方法,研究了 MAPK/ERK 通路抑制剂对 501mel 黑色素瘤细胞的全转录组、活性染色质景观和蛋白-DNA 相互作用的影响。用小分子 MEK 抑制剂 AZD6244 处理这些细胞会诱导过度色素沉着,广泛的基因表达变化,包括与色素沉着相关基因的改变,以及与 H3K27ac 活性染色质标记相关的转录上不同的调控区域的广泛表观遗传重编程。AZD6244 处理后 H3K27ac 区域差异乙酰化的调控区域富含 ETV/ETS 和 ATF 家族成员以及谱系决定因子 MITF 和 SOX10 的转录因子结合基序。被称为超级增强子的 H3K27ac 致密增强子簇显示出类似的转录因子基序富集,此外,这些超级增强子与编码 MITF、SOX10 和 ETV/ETS 蛋白的基因相关。除了全基因组活性增强子景观的重置外,MEK 抑制还导致 SOX10 在整个基因组中的广泛募集,包括在 H3K27ac 标记的增强子处增加 SOX10 结合密度。重要的是,这些被 H3K27ac 标记并被 SOX10 占据的 MEK 抑制剂反应性增强子位于黑素细胞谱系特异性和色素沉着基因附近,并与与色素沉着和黑色素瘤表型相关的许多人类 SNPs 重叠,突出了位于这些区域的变体,以便在未来的研究中优先考虑。
这些结果揭示了 MEK 抑制后 501mel 细胞中黑色素生成和发育转录程序重新激活的表观遗传重编程,并表明 MEK-SOX10 轴在这些过程的调控中广泛参与。这里鉴定的动态染色质变化为进一步分析 MAPK 通路在色素沉着和黑素细胞相关疾病中的分子机制提供了丰富的基因组资源。